Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096998 | 0.92 | HDAC11 (0.64) | HDAC11KDM4EALDH1A1 | |
| SCHEMBL20096845 | 0.88 | HDAC11 (0.66) | HDAC11HDAC6PTGER4ALDH1A1HPGD | |
| SCHEMBL20096840 | 0.87 | HDAC11 (0.83) | HDAC11HDAC6 | |
| SCHEMBL20096556 | 0.86 | HDAC11 (0.57) | HDAC11P2RX7 | |
| SCHEMBL20836890 | 0.86 | HDAC11 (0.57) | HDAC11P2RX7 | |
| SCHEMBL20096553 | 0.86 | HDAC11 (0.57) | HDAC11P2RX7 | |
| SCHEMBL29624696 | 0.86 | HDAC11 (0.57) | HDAC11P2RX7 | |
| SCHEMBL29754138 | 0.86 | HDAC11 (0.57) | HDAC11HDAC6 | |
| SCHEMBL29624687 | 0.86 | HDAC11 (0.57) | HDAC11P2RX7 | |
| SCHEMBL20096675 | 0.83 | HDAC11 (0.58) | HDAC11HDAC6P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885TSHR 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.